The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Management of Adults with JIA: Uveitis, MAS & More

Management of Adults with JIA: Uveitis, MAS & More

December 2, 2021 • By Mary Beth Nierengarten

  • Tweet
  • Email
Print-Friendly Version / Save PDF

ACR CONVERGENCE 2021—For children with juvenile idiopathic arthritis (JIA), effective treatment to achieve rapid disease control is the key to improving long-term outcomes into adulthood. This is one primary take-home message from a talk given by Mara L. Becker, MD, MSCE, professor of pediatrics and vice chair for faculty, Duke University Medical Center, Durham, N.C., during a session titled Management of Adults with JIA: Uveitis, MAS & More.

You Might Also Like
  • New Guideline Recommends Frequent Monitoring & Collaboration for JIA-Associated Uveitis Management
  • Adalimumab for JIA-Associated Uveitis: 5-Year Follow-up
  • Manifestations of JIA: JIA-Associated Uveitis, sJIA & Lung Involvement in sJIA
Also By This Author
  • A New Treatment for Axial Spondyloarthritis?

In her presentation, Dr. Becker focused on two long-term complications of JIA that could have an impact impact on the care of these patients into adulthood and underscore the need for effective, early disease control: JIA-associated uveitis and macrophage activation syndrome (MAS).

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“It is not really appropriate to take the traditional approach to escalate therapy slowly in children anymore,” she said.

Dr. Becker

JIA-Associated Uveitis

Dr. Becker opened by discussing JIA-associated uveitis, citing statistics that indicate this complication may persist into adulthood in 30–63% of patients, with varying morbidity.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Because significant sight-threatening morbidity is possible into adulthood, Dr. Becker underscored the need for rheumatologists to collaborate with ophthalmologists to screen frequently for uveitis and treat with systemic therapies when appropriate—that is when topical therapy is ineffective in controlling inflammation or can’t be tapered within three months.

Evidence to support this approach comes from general treatment guidelines Dr. Becker cited that also specify which systemic treatments are recommended, including recommendations for the use of disease-modifying anti-rheumatic drugs (DMARDs) and biologics.1 Overall, the evidence shows early DMARD treatment is associated with the best long-term outcomes. Biologics also improve outcomes, but she emphasized the that long-term data are still accumulating.

When treating severe, active, chronic anterior uveitis with sight-threatening complications, the guidelines recommend starting methotrexate and a monoclonal antibody tumor necrosis factor inhibitor (TNFi) immediately over methotrexate alone. If response to one monoclonal TNFi is inadequate at the standard JIA dose, the guidelines recommend escalating the dose or frequency of administration rather than switching to another monocolonal antibody TNFi.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“If a TNFi is instituted or required, remember that higher doses are often needed,” Dr. Becker emphasized.

Citing data from a study conducted to evaluate the different types of TNFi’s used to treat chronic uveitis in children, she said adalimumab appeared superior to infliximab and etanercept in a pooled analysis.2 However, she noted the majority of infliximab studies included in this meta-analysis used lower doses, and observational data have shown that infliximab given in much higher doses (up to 20 mg/kg) may be needed to control severe anterior uveitis.3

Pages: 1 2 | Single Page

Filed Under: ACR Convergence, Conditions, Meeting Reports, Rheumatoid Arthritis Tagged With: ACR Convergence 2021, ACR Convergence 2021 – RA, JIA, juvenile idiopathic arthritis (JIA), macrophage activation syndrome, tumor necrosis factor (TNF) inhibitors, Uveitis

You Might Also Like:
  • New Guideline Recommends Frequent Monitoring & Collaboration for JIA-Associated Uveitis Management
  • Adalimumab for JIA-Associated Uveitis: 5-Year Follow-up
  • Manifestations of JIA: JIA-Associated Uveitis, sJIA & Lung Involvement in sJIA
  • Aggressive Treatment of Inflammation Prevents Vision Loss in Patients with JIA-related Uveitis

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)